Prof Jonathan Ledermann outlines some of the key advances in ovarian cancer that have been presented at ASCO 2010. Prof Ledermann discusses research demonstrating the effectiveness of combining bevacizumab with chemotherapy as first line treatment of ovarian cancer. A second key presentation was research indicating that PARP inhibitors are effective at treating not just ovarian cancer caused by BRCA mutation but also high grade serous cancer. If this result is confirmed in further studies, it would significantly increase the number of ovarian cancer patients that could be treated with this drug.